Published in Nat Med on July 01, 1999
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med (2000) 7.46
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 3.57
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med (2004) 2.89
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res (2009) 2.02
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther (2010) 1.94
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol (2015) 1.65
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res (2013) 1.60
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48
Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med (2000) 1.46
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol (2006) 1.43
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1.36
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med (2004) 1.32
Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med (2000) 1.31
CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment. J Exp Med (2003) 1.27
CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A (2001) 1.22
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol (2006) 1.18
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol (2013) 1.16
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. Gastroenterology (2015) 1.12
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med (2009) 1.09
CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother (2013) 1.08
CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest (2013) 1.04
Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. Proc Natl Acad Sci U S A (2004) 1.03
Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol (2008) 1.03
Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials (2011) 1.02
Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest (2008) 1.02
New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol (2013) 1.01
Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma. PLoS One (2009) 1.01
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol Ther (2011) 1.00
Ethylenecarbodiimide-treated splenocytes carrying male CD4 epitopes confer histocompatibility Y chromosome antigen transplant protection by inhibiting CD154 upregulation. J Immunol (2010) 1.00
T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol (2012) 0.99
Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol (2012) 0.99
Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers (Basel) (2011) 0.99
A potent adjuvant effect of CD40 antibody attached to antigen. Immunology (2003) 0.98
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol (2012) 0.97
Immune regulatory antibodies: are they the next advance? Cancer J (2010) 0.97
On the role of the innate immunity in autoimmune disease. J Exp Med (2001) 0.97
IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. Cancer Discov (2016) 0.96
Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther (2007) 0.95
Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology (2000) 0.94
Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol (2013) 0.94
Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. J Clin Invest (2000) 0.94
Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation. J Immunol (2008) 0.93
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res (2014) 0.91
NFAT1 supports tumor-induced anergy of CD4(+) T cells. Cancer Res (2012) 0.91
Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J Immunol (2009) 0.89
Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer (2015) 0.88
Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help. PLoS One (2014) 0.88
Immunotherapy and tumor microenvironment. Cancer Lett (2015) 0.88
Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells. Cancer Gene Ther (2007) 0.87
Nuclear receptors as modulators of the tumor microenvironment. Cancer Prev Res (Phila) (2011) 0.87
Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs (2008) 0.87
A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol (2014) 0.86
Cationic liposome-mediated transfection of CD40 ligand gene inhibits hepatic tumor growth of hepatocellular carcinoma in mice. J Zhejiang Univ Sci B (2009) 0.85
CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion. Immunol Cell Biol (2013) 0.84
T cell-antigen-presenting cell interactions visualized in vivo in a model of antigen-specific inflammation. Clin Immunol (2008) 0.84
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep (2016) 0.83
Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis. Clin Exp Immunol (2002) 0.83
Mechanisms of ganglioside inhibition of APC function. J Immunol (2003) 0.83
Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody. Immunology (2010) 0.82
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology (2013) 0.82
T cells as vehicles for cancer vaccination. J Biomed Biotechnol (2011) 0.82
Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. Cancer Immunol Res (2015) 0.82
Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol (2008) 0.81
Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81
Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity. Clin Exp Immunol (2009) 0.81
Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand. J Immunol (2010) 0.80
Immunotherapy of AML: future directions. J Clin Pathol (2000) 0.80
Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity. Curr Immunol Rev (2005) 0.79
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. J Immunol (2016) 0.78
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin Cancer Res (2015) 0.78
An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen. PLoS One (2015) 0.77
Construction of recombinant eukaryotic expression plasmid containing murine CD40 ligand gene and its expression in H22 cells. World J Gastroenterol (2005) 0.77
Immune checkpoint blockade and interferon-α in melanoma. Semin Oncol (2015) 0.77
Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance. Immunology (2004) 0.76
Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol (2016) 0.76
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine (2015) 0.75
The use of immunotherapy in the treatment of melanoma. J Hematol Oncol (2017) 0.75
Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. Curr Protoc Pharmacol (2016) 0.75
Systemic treatment with anti-CD40 antibody stimulates Langerhans cell migration from the skin. Clin Exp Immunol (2002) 0.75
Immunomodulatory effects of hemagglutinin- (HA-) modified A20 B-cell lymphoma expanded as a brain tumor on adoptively transferred HA-Specific CD4+ T cells. ScientificWorldJournal (2014) 0.75
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther (2016) 0.75
CD40 therapy and surgery: a potential immunologic partnership. J Immunother (2013) 0.75
Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. J Immunol (2016) 0.75
Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr (2000) 11.69
miR-21-mediated tumor growth. Oncogene (2006) 9.90
Mutations in the K+ channel signature sequence. Biophys J (1994) 6.81
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
Comparative genomics of foot-and-mouth disease virus. J Virol (2005) 3.42
New tumor markers: CA125 and beyond. Int J Gynecol Cancer (2005) 2.92
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ (2001) 2.85
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 2.81
Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol (1989) 2.70
North American and European porcine reproductive and respiratory syndrome viruses differ in non-structural protein coding regions. J Gen Virol (1999) 2.68
The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J (1999) 2.67
Cell polarity: an examination of its behavioral expression and its consequences for polymorphonuclear leukocyte chemotaxis. J Cell Biol (1981) 2.64
The genome of fowlpox virus. J Virol (2000) 2.30
Demonstration of epidermal growth factor-induced receptor dimerization in living cells using a chemical covalent cross-linking agent. J Biol Chem (1988) 2.30
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
Prototype systems for rechargeable magnesium batteries. Nature (2000) 2.26
Involvement of Ral GTPase in v-Src-induced phospholipase D activation. Nature (1995) 2.16
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 2.13
Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 2.10
Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol (1997) 2.10
HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm (2000) 2.05
Umbilical cord mesenchymal stem cell transplantation in drug-induced Stevens-Johnson syndrome. J Eur Acad Dermatol Venereol (2012) 2.03
A novel high-affinity inhibitor for inward-rectifier K+ channels. Biochemistry (1998) 1.95
Coupled ion movement underlies rectification in an inward-rectifier K+ channel. J Gen Physiol (1998) 1.94
In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity (1996) 1.89
Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. J Biol Chem (1997) 1.86
Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J (1988) 1.86
Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle. Cardiovasc Res (2000) 1.86
The genome of Melanoplus sanguinipes entomopoxvirus. J Virol (1999) 1.84
An African swine fever virus gene with similarity to the proto-oncogene bcl-2 and the Epstein-Barr virus gene BHRF1. J Virol (1993) 1.83
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology (2006) 1.81
Genomes of the parapoxviruses ORF virus and bovine papular stomatitis virus. J Virol (2004) 1.79
Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene (2010) 1.78
CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells. J Immunol (2001) 1.77
Effects of Ca2+ on the kinetics of phosphate release in skeletal muscle. J Biol Chem (1992) 1.77
T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74
The genome of a very virulent Marek's disease virus. J Virol (2000) 1.71
Vav1/Rac-dependent actin cytoskeleton reorganization is required for lipid raft clustering in T cells. J Cell Biol (2001) 1.70
The genomes of sheeppox and goatpox viruses. J Virol (2002) 1.68
DANCE, a novel secreted RGD protein expressed in developing, atherosclerotic, and balloon-injured arteries. J Biol Chem (1999) 1.62
Removing a barrier to computer-based outbreak and disease surveillance--the RODS Open Source Project. MMWR Morb Mortal Wkly Rep (2004) 1.60
Mechanism of IRK1 channel block by intracellular polyamines. J Gen Physiol (2000) 1.60
A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA (1982) 1.58
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Altered expression of HOXA10 in endometriosis: potential role in decidualization. Mol Hum Reprod (2007) 1.57
Mechanism of inhibition of tannic acid and related compounds on the growth of intestinal bacteria. Food Chem Toxicol (1998) 1.56
The genome of canarypox virus. J Virol (2004) 1.56
Identification of a new mouse beta-chemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells. J Immunol (1997) 1.53
Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol (2007) 1.53
CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med (2000) 1.48
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48
[Effect of temperature and food on Spodoptera litura population]. Ying Yong Sheng Tai Xue Bao (2000) 1.47
A plasmid expression system for quantitative in vivo biotinylation of thioredoxin fusion proteins in Escherichia coli. Nucleic Acids Res (1998) 1.45
An African swine fever virus virulence-associated gene NL-S with similarity to the herpes simplex virus ICP34.5 gene. J Virol (1996) 1.44
A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med (1995) 1.44
An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J (2000) 1.43
Genome of horsepox virus. J Virol (2006) 1.42
The genome of turkey herpesvirus. J Virol (2001) 1.42
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41
Synthesis of a stable form of tertiapin: a high-affinity inhibitor for inward-rectifier K+ channels. Biochemistry (1999) 1.41
Lessons from a review of thyroglobulin assays in the management of thyroid cancer. Intern Med J (2008) 1.40
Laboratory investigation of ecological factors influencing the environmental presence of Burkholderia pseudomallei. Microbiol Immunol (1996) 1.40
Fifteen-year global time series of satellite-derived fine particulate matter. Environ Sci Technol (2014) 1.37
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (2010) 1.36
Tuning the voltage dependence of tetraethylammonium block with permeant ions in an inward-rectifier K+ channel. J Gen Physiol (1999) 1.34
Mechanism of cGMP-gated channel block by intracellular polyamines. J Gen Physiol (2000) 1.34
Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther (1995) 1.34
Genome sequence of a baculovirus pathogenic for Culex nigripalpus. J Virol (2001) 1.32
Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene (2009) 1.31
The genome of swinepox virus. J Virol (2002) 1.30
Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res (2000) 1.30
The Tlx-2 homeobox gene is a downstream target of BMP signalling and is required for mouse mesoderm development. Development (1998) 1.29
Structure and function in rhodopsin. Separation and characterization of the correctly folded and misfolded opsins produced on expression of an opsin mutant gene containing only the native intradiscal cysteine codons. Biochemistry (1995) 1.28
Preclinical diagnosis of African swine fever in contact-exposed swine by a real-time PCR assay. J Clin Microbiol (2005) 1.27
Phylogenetic comparison of classical swine fever virus in China. Virus Res (2001) 1.26
Epidemiological model for Clostridium difficile transmission in healthcare settings. Infect Control Hosp Epidemiol (2011) 1.26
Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med (1983) 1.26
Close correspondence between the action spectra for the blue light responses of the guard cell and coleoptile chloroplasts, and the spectra for blue light-dependent stomatal opening and coleoptile phototropism. Proc Natl Acad Sci U S A (1996) 1.25
Analysis of 74 kb of DNA located at the right end of the 330-kb chlorella virus PBCV-1 genome. Virology (1997) 1.24
A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther (1999) 1.24
Identification and characterization of embryonic stem cell-derived pacemaker and atrial cardiomyocytes. FASEB J (2005) 1.24
Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. Biochem Biophys Res Commun (2001) 1.23
Mechanisms of inward-rectifier K+ channel inhibition by tertiapin-Q. Biochemistry (1999) 1.22
Role of FOXO1A in the regulation of insulin-like growth factor-binding protein-1 in human endometrial cells: interaction with progesterone receptor. Biol Reprod (2005) 1.22
Association between v-Src and protein kinase C delta in v-Src-transformed fibroblasts. J Biol Chem (1997) 1.22
Pore block versus intrinsic gating in the mechanism of inward rectification in strongly rectifying IRK1 channels. J Gen Physiol (2000) 1.21
Kinetics of inward-rectifier K+ channel block by quaternary alkylammonium ions. dimension and properties of the inner pore. J Gen Physiol (2001) 1.21